Evidence map›Paper›PMID 20161589›Full record

ArticleProteomics. Clinical applications2009

Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease.

Bruce A Julian, Hitoshi Suzuki, Yusuke Suzuki, Yasuhiko Tomino, Goce Spasovski, Jan Novak

Abstract read
In one paragraph

Article in Proteomics. Clinical applications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Urinary immunoglobulins in viral diagnosis: An overview.The Indian journal of medical research · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bruce A JulianUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Hitoshi Suzuki
Yusuke Suzuki
Yasuhiko Tomino
Goce Spasovski
Jan Novak

Funding

Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6M
UAB CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCTS) UL1: BPCAUL1RR025777 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUAY-WOODFORD, LISA MARIE · 2008 to 2011
$22.3M
Immune Complexes and Mesangial Cells in IGA NephropathyP01DK061525 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2002 to 2006
$6.7M
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR01DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAN NOVAK · 2007 to 2026
$6.0M
Mucosal HIV and Immunobiology CenterR24DK064400 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SMITH, PHILLIP D · 2003 to 2012
$4.8M
Analytical tools for the analysis of clustered O-glycans in clinical samplesR01GM098539 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RENFROW, MATTHEW B · 2011 to 2019
$2.7M
IgA1 glycosylation and receptor interactions in IgA nephropathyR01DK071802 · NIDDK · UNIVERSITY OF CINCINNATI · PI HERR, ANDREW B · 2006 to 2010
$1.5M
IgA-secreting B cell lines: a novel tool for studies of IgA nephropathyR21DK080301 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN · 2008 to 2009
$399k
Accurate profiles of IgA1 O-glycan heterogeneity in IgA nephropathyR21DK077279 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RENFROW, MATTHEW B · 2008 to 2009
$388k
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR56DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN · 2012 to 2012
$92k
NCRR NIH HHS M01 RR000032NCRR NIH HHS UL1 RR025777NIDDK NIH HHS P01 DK061525NIDDK NIH HHS R01 DK071802NIDDK NIH HHS R01 DK078244NIDDK NIH HHS R21 DK077279NIDDK NIH HHS R21 DK080301NIDDK NIH HHS R24 DK064400NIDDK NIH HHS R56 DK078244NIGMS NIH HHS R01 GM098539
6 · The paper itself

Abstract

Renal disorders account for a substantial fraction of the budget for health care in many countries. Proteinuria is a frequent manifestation in afflicted patients, but the origin of the proteins varies based on the nature of the disorder. The emerging field of urinary proteomics has the potential to replace kidney biopsy as the diagnostic procedure of choice for patients with some glomerular forms of renal disease. To fully realize this potential, it is vital to understand the basis for the urinary excretion of protein in physiological and pathological conditions. In this review, we discuss the structure of the nephron, the functional unit of the kidney, and the process by which proteins/peptides enter the urine. We discuss several aspects of proteinuria that impact the proteomic analysis of urine of patients with renal diseases.

Identifiers

PMID20161589
PMCPMC2808139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.